StockNews.AI
ALNY
StockNews.AI
152 days

Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

1. ALNY received FDA approval for AMVUTTRA for treating ATTR-CM in adults. 2. This approval aims to reduce cardiovascular mortality and hospitalizations.

FDA Approval
+11.75%Current Return
VS
-0.27%S&P 500
$253.54503/20 06:06 PM EDTEvent Start
$283.3403/22 12:19 AM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Very Bullish?

FDA approval often leads to stock price increases; historical examples include companies like Moderna post-vaccine approvals.

How important is it?

FDA approvals significantly enhance product credibility and market potential, directly influencing ALNY’s growth.

Why Short Term?

Immediate market reactions are expected upon the news of FDA approval.

Related Companies

MDGNMRNAEXAS
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the U.S. Food and Drug Administration (FDA) approval of the supplemental New Drug Application (sNDA) for its RNAi therapeutic, AMVUTTRA® (vutrisiran), for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failu.

Related News